麻豆传媒

Start , Janssen's head of global oncology therapeutics advised pharma executives during a virtual meeting. (Fierce Pharma)

Patients with early-stage, HER2-negative, BRCA-mutant breast cancer should be offered (Lynparza) following neoadjuvant therapy and local treatment, according to a rapid guideline update from the American Society of Clinical Oncology.

"Give me one more hug." When during an oncologist's last meeting with a dying patient. (JCO: Art of Oncology)

A phase I trial of the IDH1/2 inhibitor vorasidenib in showed a favorable safety profile, an objective response rate of 18%, and a median progression-free survival of 3.1 years, Servier announced.

A survey by the American Academy of Dermatology showed that only a third of Americans are concerned about developing , even though 70% may have one or more risk factors.

Results of a phase I/II trial of the pralsetinib (Gavreto) showed response rates of 60% to 90% in RET fusion-positive non-small cell lung cancer and RET fusion-positive or RET-mutant thyroid cancer. (University of Texas MD Anderson Cancer Center)

Uncovering more clues to the association between . (Cell Reports, Arizona State University)

A showed potential for predicting outcomes with immunotherapy for bladder cancer. (Nature)

Legislation introduced in both houses of Congress would ban a class of known as PFAS from a variety of widely used cosmetics. (CNN)

Blueprint Medicines announced FDA approval of avapritinib (Ayvakit) for adults with . Read 麻豆传媒's coverage of a study that supported the approval.

Does affect breast cancer survival? (Journal of Clinical Oncology)

Comment